Completed
PHASE3
INTERVENTIONAL
NCT04660643
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss. The study had two phases: a lead-in phase in which all participants took tirzepatide and a treatment phase in which participants either continued tirzepatide or switched to placebo. The study lasted about 2 years (25 visits).
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
OTHER
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Randomization in Body Weight at Week 88
TimeFrame:
Randomization (Week 36), Week 88
Description:
Least square (LS) mean was analysed by mixed model repeated measures (MMRM) model with randomization + analysis country + sex + interactive web response system (IWRS) MTD at Week 36 + treatment + time + treatment\*time (Type III sum of squares) as variables.
Trial Information
NCT ID
NCT04660643
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025